Below is a list of clinical trials currently being recruited for. For more information on clinical trials or to participate in one of our open trials, please contact our Research Coordinator via email or via phone at 856-218-5790.
|A011106 - Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neoadjuvant Treatment (ALTERNATE) in postmenopausal women: A Phase III Study
||This study is a clinical trial looking at options for treating the cancer before you have surgery.
||One purpose of this study is to determine whether
Fulvestrant (faslodex), or fulvestrant plus arimidex, is superior than arimidex alone in shrinking the tumor before surgery. An important part of this trial is to examine whether
the breast cancer is responding adequately to the endocrine (drug) therapy drug by measuring a growth marker in the cancer called Ki67.
|S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
||Patients are given everolimus or placebo daily for one year.
||The primary objective of this study is to compare whether the addition of one year of
everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive
disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive
and HER2-negative breast cancer.
|S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer
||RxPONDER's goal is to help doctors and their patients with breast cancer make better treatment decisions by using a genomic test known as the Oncotype DX® Assay. Patients with hormone receptor-positive breast cancer that has spread to their lymph nodes usually get both chemotherapy and hormonal therapy after surgery. But for some of these patients with low to intermediate "recurrence scores" on the Oncotype DX test, chemotherapy may offer little or no benefit. Hormonal therapy alone may be enough.
||For patients with node-positive, hormone-receptor positive, HER2 negative breast cancer who also have low to intermediate Oncotype DX recurrence scores, what are the benefits -- if any -- from adding chemotherapy to hormonal therapy after surgery?
|NRG-BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
||For Patients with Triple Negative breast cancer
||This trial adds another chemotherapy agent to the standard treatment to see if this will improve disease free survival
|Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
|Screening Trial for Lung Cancer patients
||The purpose of the trial is to test the tumor cells of patients with a certain type of lung cancer to see if they have any genetic changes that would respond to targeted drug therapy.
|EAY131 Molecular Analysis for Therapy Choice (MATCH)
||Screening study for patient with Refractory solid tumors or lymphomas
||The purpose of the study is to determine if targeted therapy will work better than standard chemotherapy in patients whose tumors are refractory to treatment and no other standard treatment exsists.
|C80702 A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
||A trial of standard chemotherapy vs chemotherapy plus celebrex
||This trial asks the question Does less chemotherapy work as well (previous studies show it does) and does the addition of Celebrex improve outcomes
Clinical Trial Links
HOPE - Helping Oncology Patients Exercise - 08/01/2016
Open to adult cancer patients of all ages and fitness levels. Research suggests exercise can help cancer patients reduce pain, nausea, anxiety and fatigue, improve ability to perform daily activities and enhance mood.
Well-Being Yoga - Tuesday Afternoon - 08/02/2016
Yoga, which increases flexibility, range of motion and strength, may bring additional benefits both during and after cancer treatments. When tension is released, energy flows more easily in the body, allowing participants to experience a sense of well-being.